A 2026 umbrella review of 16 systematic reviews covering 371 trials found strong medication evidence for tobacco and opioid use disorders, modest benefits for alcohol use disorder, and no approved drugs for stimulant or cannabis use disorders.1 Varenicline more than doubled smoking quit rates vs. placebo, methadone kept people in opioid treatment longer than buprenorphine, …
A Global Burden of Disease analysis estimated that U.S. age-standardized substance-use disorder disability-adjusted life-year rates rose 213.5% from 1990 to 2019, with opioid use disorders producing the steepest increase and the largest state-level burden.1 Research Highlights U.S. cases rose sharply: prevalent substance-use disorder cases increased from 12.6 million in 1990 to 19.5 million in 2019.1 …
The relationship between cannabis use (CU) and anxiety disorders (AD) is a topic of ongoing debate and research within the scientific community. While some studies suggest cannabis can have anxiolytic (anxiety-reducing) effects, others point to anxiogenic (anxiety-inducing) outcomes, especially with habitual use. This nuanced interplay between cannabis and anxiety highlights the importance of understanding individual …